These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 34461363

  • 1. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS, Kuzu Kumcu M, Tezcan Aydemir S, Akbostanci MC.
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [Abstract] [Full Text] [Related]

  • 2. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice.
    Scaglione F.
    Toxins (Basel); 2016 Mar 04; 8(3):. PubMed ID: 26959061
    [Abstract] [Full Text] [Related]

  • 3. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
    Bihari K.
    Curr Med Res Opin; 2005 Mar 04; 21(3):433-8. PubMed ID: 15811212
    [Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH, Cetinkaya A, Kulwin DR.
    Clin Exp Ophthalmol; 2014 Apr 04; 42(3):254-61. PubMed ID: 23844601
    [Abstract] [Full Text] [Related]

  • 5. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG, Tyrrell EG, Grosset KA.
    J Rehabil Med; 2015 Feb 04; 47(2):183-6. PubMed ID: 25325305
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1.
    Sampaio C, Ferreira JJ, Simões F, Rosas MJ, Magalhães M, Correia AP, Bastos-Lima A, Martins R, Castro-Caldas A.
    Mov Disord; 1997 Nov 04; 12(6):1013-8. PubMed ID: 9399229
    [Abstract] [Full Text] [Related]

  • 8. Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.
    Badarny S, Ibrahim R, Susel Z, Zaina A, Nasar R, Badarny Y.
    Medicine (Baltimore); 2021 Jun 25; 100(25):e26481. PubMed ID: 34160460
    [Abstract] [Full Text] [Related]

  • 9. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S, Susel Z, Honigman S.
    Isr Med Assoc J; 2008 Jul 25; 10(7):520-2. PubMed ID: 18751631
    [Abstract] [Full Text] [Related]

  • 10. Comparison of techniques of botulinum toxin injections for blepharospasm and hemifacial spasm.
    Sacramento DRC, Lima A, Maia DP, Cunningham M, Maciel RH, Camargos ST, Cardoso F.
    Mov Disord; 2019 Sep 25; 34(9):1401-1403. PubMed ID: 31251420
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm.
    Nüssgens Z, Roggenkämper P.
    Graefes Arch Clin Exp Ophthalmol; 1997 Apr 25; 235(4):197-9. PubMed ID: 9143885
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intradetrusor injections of onabotulinum toxin A (Botox®) 300 U or 200 U versus abobotulinum toxin A (Dysport®) 750 U in the management of neurogenic detrusor overactivity: A case control study.
    Peyronnet B, Castel-Lacanal E, Roumiguie M, Even L, Marque P, Soulié M, Rischmann P, Game X.
    Neurourol Urodyn; 2017 Mar 25; 36(3):734-739. PubMed ID: 27037973
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG, Cardoso IP, Saraiva FP, Raiza AC, Tanaka LK, Matayoshi S.
    Arq Bras Oftalmol; 2006 Mar 25; 69(3):319-22. PubMed ID: 16936952
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Experience with long-term treatment with albumin-supplemented botulinum toxin type A.
    Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R.
    J Neural Transm (Vienna); 2009 Apr 25; 116(4):437-41. PubMed ID: 19319477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.